anti-TCR C beta 1 (human), mAb (Jovi-1) (preservative free)
| Code | Size | Price |
|---|
| ANC-101-820-100ug | 100 ug | £332.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: Mouse IgG2a
Antibody Clonality: Monoclonal
Antibody Clone: Jovi-1
Regulatory Status: RUO
Target Species: Human
Application: Flow Cytometry
Shipping:
BI
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
TCRB; T Cell Receptor beta Locus; TRBC1
EClass:
32160000
Form (Short):
liquid
Formulation:
50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl
Handling Advice:
Avoid freeze/thaw cycles.
Immunogen:
Human HA1.7 TCR beta chain expressed on transgenic mouse cells.
Labels - Conjugates:
Preservative Free
Long Description:
Monoclonal Antibody. Isotype: Mouse IgG2a. Clone: Jovi-1. Applications: FACS. 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl Human T cell receptor (TCR) is a T cell surface expressed heterodimer of alpha/beta or gamma/delta chains. TCR?s recognize antigen peptides bound to MHC molecules forming the basis of antigen specific response by T cells.
Package Type:
Plastic Vial
Product Description:
Human T cell receptor (TCR) is a T cell surface expressed heterodimer of alpha/beta or gamma/delta chains. TCR?s recognize antigen peptides bound to MHC molecules forming the basis of antigen specific response by T cells. This specific TRBC1 antibody has been described to be useful in a simplified immunophenotypic assessment of T cell clonality.
Purity:
>95% (SDS-PAGE)
Source / Host:
Purified from concentrated hybridoma tissue culture supernatant.
Specificity:
Recognizes human Cbeta1 TCR gene product (TRBC1) and reacts with 50-75% of T cells in normal human blood. Does not bind to TCR Cbeta2 (TRBC2).
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at +4°C.
References
Generation of monoclonal antibodies against a human T cell receptor beta chain expressed in transgenic mice: J.L. Viney, et al.; Hybridoma 11, 701 (1992) | T cell antigen receptor signal transduction: a tale of tails and cytoplasmic protein-tyrosine kinases: A. Weiss, et al.; Cell 73, 209 (1993) | Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies: P.M. Maciocia, et al.; Nat. Med. 23, 1416 (2017) | Single Antibody Detection of T-Cell Receptor alphabeta Clonality by Flow Cytometry Rapidly Identifies Mature T-Cell Neoplasms and Monotypic Small CD8-Positive Subsets of Uncertain Significance: M. Shi, et al.; Cytometry B Clin. Cytom. 98, 99 (2020)
Related Products
| Product Name | Product Code | Supplier | anti-TCR C beta 1 (human), mAb (Jovi-1) | ANC-101-020 | Ancell | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| anti-TCR C beta 1 (human), mAb (Jovi-1) (Biotin) | ANC-101-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-TCR C beta 1 (human), mAb (Jovi-1) (FITC) | ANC-101-040 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-TCR C beta 1 (human), mAb (Jovi-1) (R-PE) | ANC-101-050 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-TCR V beta 3 (human), mAb (Jovi-3) | ANC-102-020 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-TCR V beta 3 (human), mAb (Jovi-3) (Biotin) | ANC-102-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-TCR V beta 3 (human), mAb (Jovi-3) (FITC) | ANC-102-040 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-TCR V beta 3 (human), mAb (Jovi-3) (R-PE) | ANC-102-050 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-TCR V beta 3 (human), mAb (Jovi-3) (preservative free) | ANC-102-820 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||